Malaysia Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Malaysia Pharmaceuticals & Healthcare Report

The Malaysia Pharmaceuticals and Healthcare Report

Independent 5-year pharmaceutical and healthcare industry forecasts for Malaysia .

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Malaysian pharmaceutical and healthcare industry.

Competitive intelligence, Malaysian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Malaysian market.

The Malaysia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Malaysia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Malaysian pharmaceutical and healthcare industry.

Key Benefits of Report

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Malaysia Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Table of Contents

Chapter - Executive Summary

Malaysia Pharmaceuticals And Healthcare Industry SWOT
Malaysia Political SWOT
Malaysia Economic SWOT
Malaysia Business Environment SWOT

Chapter - Pharmaceutical Business Environment Ratings

Table: Asia Pacific Business Environment Rankings For Q209
Limits Of Potential Returns
Risks To Realisation Of Returns

Chapter - Malaysia: Market Summary

Regulatory Regime
Pharmaceutical And Medical Advertising
Recent Regulatory Developments
Intellectual Property Regime
Counterfeit Pharmaceuticals
Compulsory Licensing
Free Trade Agreements
Pricing And Reimbursement

Chapter - Industry Trends And Developments

Epidemiology
Table: 10 Leading Causes Of Death In Ministry of Health Hospitals, 2005
Healthcare Sector
Healthcare Sector Funding
Recent Healthcare Sector Developments
Pharmaceutical Sector
Table: BMI's Crisis Recovery Rating – Malaysia
Pharmaceutical Demand
Domestic Company Activity
Halal Medicine
Traditional Medicine
Biotechnology And Research
Table: Key Points Of The Malaysian National Biotechnology Policy
Table: The Benefits Of Conducting Biotechnology Research In Malaysia
Recent Biotechnology Developments
Tables: Examples Of Pharmaceuticals From Natural Sources
Clinical Trials
Medical Devices
Table: Malaysia – Clinical Diagnostics Market, 2006 (US$mn)
Leading Medical Device Players
Recent Developments In The Medical Devices Industry

Chapter - Industry Forecast Scenario

Overall Market Forecast
Table: Malaysia – Drug Expenditure Indicators, , 2003-2013
Key Growth Factors – Industry
Table: Malaysia – Health Expenditure Indicators, 2003-2013
Key Growth Factors – Macroeconomic
Table: Malaysia – Economic Activity, 2005-2013
Prescription Market Forecast
Table: Malaysia – Prescription Market Indicators, Historical Data And Forecasts (MYRmn unless otherwise stated)
Patented Market Forecast
Table: Malaysia – Patented Drug Market Indicators, 2003-2013
Generic Drug Market Forecast
Table: Malaysia – Generics Drugs Market Indicators, 2003-2013
OTC Market Forecast
Table: Malaysia – OTC Drug Market Indicators, 2003-2013 (MYRmn unless otherwise stated)
Pharmaceutical Trade Forecast
Table: Malaysia – Pharmaceutical Trade Indicators, 2003-2013 (US$mn)
Other Healthcare Data Forecasts
Table: Malaysia – Other Healthcare Indicators, 2003-2013
Key Risks To BMI's Forecast Scenario

Chapter - Competitive Landscape

Table: Malaysia Pharmaceutical Market, Q406
Table: Malaysia – Leading Firms By 2005 Sales
Table: Malaysia – Estimated Spending On Leading 20 Drugs, 2004

Chapter - Company Profiles

Multinational Companies
GlaxoSmithKline (GSK)
Pfizer
Novartis
Merck & Co
Sanofi-Aventis
Ranbaxy Malaysia
Eli Lilly Malaysia
Leading Indigenous Manufacturers
Pharmaniaga
Asia Pharmaceutical Products (APP)
Prime Pharmaceutical
Bumimedic
Hovid
Chemical Company of Malaysia (CCM)
Kotra Pharma
YSP Southeast Holding

Chapter - Country Snapshot: Malaysia Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000-2003
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Manufacturing Wages, 2000-2012

Chapter - BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Malaysia Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Executive Summary

In the BMI Business Environment Ranking matrix for Q209, Malaysia returned to eight position (from tenth previously), out of the 15 key regional markets surveyed in the Asia Pacific region. Key attractions of the Malaysian pharmaceutical market are the government’s encouragement of the biotechnology sector and the forecast strong annual growth in the country’s pharmaceutical market, which is expected to develop at a compound annual growth rate (GAGR) of 11.85% in local currency terms. Consequently, from being worth around MYR3.29bn (US$0.97bn) in 2008, the consumer value of market is expected to increase to MYR5.75bn (US$1.89bn) in 2013. However, given that per capita pharmaceutical consumption is quite low, especially due to the high out-of-pocket payment levels, patented medicines are likely to grow at a slower pace than generics, despite regulatory improvements targeting the considerable counterfeit activity in the country. In the meantime, the Malaysian economy expanded by a mere 0.1% in Q408, increasing fears that an outright recession may be on the cards in 2009, which also threatens out-of-pocket payments for healthcare and pharmaceuticals.

Nevertheless, the demand for chronic and long-term treatments will continue to rise, given improved survival rates and the slowly ageing population. According to the February 2009 statement by the Health Minister, some 43% of all Malaysians aged 30 or above are at risk of hypertension, with estimates suggesting that some 4.8mn Malaysians are already affected by the condition. Around the same time, the Public Health Medicine Specialist Association of Malaysia began a year-long study into the financial burden of cervical cancer in the country, which is supported by the local subsidiary of the major UK-based drugmaker GlaxoSmithKline (GSK). The research will assess the current costs of human papilloma virus (HPV)-related cervical cancer, while also give costs of the national HPV vaccination programme, which would provide a considerable boost to HPV vaccine manufacturers.

In terms of company news, one of leading local drugmakers, YSP Southeast Asia Holding, maintained expectations of a robust financial trajectory, despite the global economic downturn. The company stated that its focus on prescription drugs, after-sales service and strong branding in the generics sector will ensure profit growth in 2009. Foreign companies are also predicting growth of the generics sector, with US-based generics specialist SOHM Inc. recently expanding its distribution to South East Asia, including Malaysia, Thailand.

Similarly, the research and development (R&D) sector in Malaysia has welcomed the news that Swiss pharmaceutical major Novartis plans to search the rich ecology of the Malaysian state of Sarawak for new medicines. Given the rewards on offer and the drop in productivity from synthetic drug discovery, other innovative pharmaceutical companies are likely to engage in similar activities. Malaysia’s destination for R&D investment is considerable, given its excellent infrastructure, a business-friendly government, and a welleducated, English-speaking population.

Malaysia Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Read about our other Pharmaceuticals & Healthcare Reports

Africa

Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe

Asia

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam

Caribbean

Puerto Rico

Europe

Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan

Latin America

Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela

Middle East

Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates

North America

Canada and United States
Business Monitor International Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 25 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.